Table 2 Outcomes of clinical trials using mosunetuzumab in aggressive lymphomas
From: Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
Disease | Regimen | Dosing (mg) | ORR/OR | PFS/OS/DOR | CRS/ICANS | Reference |
|---|---|---|---|---|---|---|
aLBCL 1st line | M | M I.V. 8–17 cycles 1/2/13.5 1/2/30 | 56%/43% | 12 months PFS 39% (25.8–52.8) 12 months OS 75% (63.4–86.8) | CRS: 44%, 2% ≥ grade 3 ICANS: 4.4%, 0% ≥ grade 3 | 5 |
aNHL | M | Subq. 8–17 cycles 5/15/45 5/45/45 5/90/45 | 37%/20% | Median DOR 6.1 months (4.6-NE) | CRS: 28%, 0% ≥ grade 3 ICANS: 3.4%, 0% ≥ grade 3 | 4 |
aLBCL  > 1 line | M + Pola | M: I.V. 8–17 cycles Pola: 6 cycles | 65%/48% | Median PFS: 8.9 months (95% CI: 3.5, NE) | CRS: 18%, 0% ≥ grade 3 ICANS: 7.9%, 3.2% ≥ grade 3 | 6 |